Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of NTM-1632 in Healthy Adults
NCT02779140Phase 1Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Aug 2016
- Primary completion
- May 2017
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of NTM-1632 in botulism (3 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Occurrence of Adverse Events, Changes from baseline in clinical safety laboratory values at Day 91 and 4 more. Started Aug 2016; status: completed.
02
Drugs
NTM-1632
03
Conditions
botulism
Beyond the preview
Go deeper on NCT02779140.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02779140.